All In Biotech

Drug Trial Radar · NCT07406334

A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Toddlers 12 to 15 Months of Age Receiving a Single Booster Dose

A Phase 1, Observer-Blind, Randomized, Active Controlled Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Toddlers 12 To 15 Months of Age Receiving a Single Booster Dose

Last checked: Nov 20, 2026Latest source record: Sep 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

46

Actual

Start

May 15, 2026

Primary completion

Feb 22, 2027

Study completion Feb 22, 2027

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Feb 12, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 12 months, up to 15 months
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The main purpose of this study is to assess the safety and reactogenicity of a single dose of the new pneumococcal vaccine (called Pn-MAPS30plus) in toddlers who have previously completed a two-dose primary vaccination series with PCV used in local immunization program. PCV20 will be used as a comparator for this study.

Conditions

  • Pneumonia, Bacterial

Interventions

  • Pn-MAPS30plusBiological

    Pn-MAPS30plus vaccine will be administered intramuscularly.

  • PCV20Combination product

    PCV20 vaccine will be administered intramuscularly.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Solicited Administration site Adverse Events (AEs)Time frame: Day 1 to Day 7
  2. Number of Participants with Solicited Systemic Adverse Events (AEs)Time frame: Day 1 to Day 7
  3. Number of Participants with Unsolicited AEsTime frame: Day 1 to Day 30
  4. Number of Participants with Serious AEs (SAEs), Adverse Events of Special Interest (AESIs) and AEs Leading to WithdrawalTime frame: Day 1 up to trial end (Month 6)
  5. Number of Participants with Hematological and Biochemical Laboratory AbnormalitiesTime frame: On Day 8 compared to Day 1 (pre-vaccination)

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Pretoria, South Africa

  • GSK Investigational Site

    Soweto, Johannesburg, Gauteng, South Africa

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.